To learn about the safety and tolerability of study drug combinations in patients with relapsed/refractory, IDH1-mutated myeloid malignancies with a co-signali…

Targeted TherapyIDH1-Mutated MalignanciesMutations

~Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07032727

Observational

Patient-centered, Optimal Integration of Survivorship and Palliative Care

The goal of this study is to develop and test the feasibility of a supportive care model (POISE) for patients with metastatic Non-small Cell Lung Cancer (NSCLC…

Stage IV Non-small Cell Lung CancerTargeted TherapyNonsmall Cell Lung Cancer+5 more

~Estimated

~$10 – $6,250

Massachusetts General HospitalNCT04900935

Phase 1

An Open-label and Dose-escalation Phase I Clinical Study to Evaluate the Tolerability, Safety, and Pharmacokinetics of HLA-G-targeted Exosome (SOB100) in Healthy Subjects

The investigational drug, SOB100, is an HLA-G targeted exosome equipped with a nanobody namely anti-HLA-G VHH on the exosome membrane. This is a Phase I dose e…

Healthy SubjectsExosomeTargeted Therapy

~Estimated

~$10 – $8,750

Shine-On Biomedical Co., Ltd.NCT07219940